Our products & pipeline

What has EpiAxis discovered?

• The pivotal role that nuclear LSD1 plays in reprograming the epigenome in metastatic disease in relation to both tumour initiating and immune cells.
• The LSD1 mediated epigenetic signatures for chemotherapy and immunotherapy resistance in both tumour initiating cells and exhausted immune cells that drive recurrence of metastatic disease.
• Targeting the enriched nuclear pool of LSD1 reverses the resistant epigenetic signatures and removes immune checkpoint blockage, without the use of a checkpoint inhibitor, to prevent recurrence.
• A proprietary, non-catalytic, peptidomimetic way to superiorly inhibit the nuclear pool of LSD1 in both tumour initiating cells and in exhausted immune cells.

Why is EpiAxis best in class?

• We exclusively target the nuclear pool of LSD1 without catalytic interference.
• We provide three differentiated modes of action to target the innate nuclear pool of LSD1.
• We offer superior phenotype reversal and immune reinvigoration when compared to all known catalytic inhibitors.
• We offer superior removal of immune checkpoint blockage without the use of a checkpoint inhibitor when compared to all known catalytic inhibitors.
• We have proprietary LSD1 inhibitors with National Phase prosecutions active in eight jurisdictions.

What are our clinical findings to date?

• LSD1 inhibition reduces the mesenchymal burden of CTCs.
• LSD1 inhibition enhances effector memory T cells.
• LSD1 inhibition consistently increases IFNg and perforin expression in CD8+ T cells in remission.
• LSD1 inhibition offers superior immune reinvigoration regardless of HER2 status.
• LSD1 inhibition re-invigorates & re-programs T-cells & improves anti-tumour immune response.
• LSD1 inhibition re-programs CTLA4 protein expression in CD8+ T cells.
• LSD1 inhibition diminishes mesenchymal and stem-like phenotypes and in doing so, removes the CTC burden.
• EpiAxis’ EPI-110 candidates appear to be highly efficacious compared to phenelzine sulfate.

What are our development plans?

EpiAxis is now seeking a commercial partner to work with it to move its EPI-110 assets into a range of clinical studies in Europe and USA, which it expects will lead to regulatory approval in all major global markets.

EpiAxis believes that its EPI-110 candidates are not only ‘first in class’ but unequivocally ‘best in class’ inhibitors’ for solid tissue tumours.  The Company further envisages that its EPI-110 candidates, as non-catalytic inhibitors, will be co-administered with chemotherapy and other IO agents, as Standard of Care, to prevent both mBC recurrence and other metastatic disease, in both the adjuvant and neoadjuvant setting.